The repertoire of desaturases and elongases reveals fatty acid variations in 56 eukaryotic genomess⃞

by Kosuke Hashimoto, Akiyasu C. Yoshizawa, Shujiro Okuda, Keiichi Kuma, Susumu Goto, Minoru Kanehisa
Published 2008-01-01

Attention network for predicting T-cell receptor–peptide binding can associate attention with interpretable protein structural properties

by Kyohei Koyama, Kyohei Koyama, Kyohei Koyama, Kosuke Hashimoto, Chioko Nagao, Kenji Mizuguchi, Kenji Mizuguchi, Kenji Mizuguchi
Published 2023-12-01

Cancer missense mutations alter binding properties of proteins and their interaction networks.

by Hafumi Nishi, Manoj Tyagi, Shaolei Teng, Benjamin A Shoemaker, Kosuke Hashimoto, Emil Alexov, Stefan Wuchty, Anna R Panchenko
Published 2013-01-01

Raman Study on Lipid Droplets in Hepatic Cells Co-Cultured with Fatty Acids

by Pradjna N. Paramitha, Riki Zakaria, Anisa Maryani, Yukako Kusaka, Bibin B. Andriana, Kosuke Hashimoto, Hiromitsu Nakazawa, Satoru Kato, Hidetoshi Sato
Published 2021-07-01

Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer

by Kosuke Hashimoto, Kyoichi Kaira, Ou Yamaguchi, Atsuto Mouri, Ayako Shiono, Yu Miura, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu, Ichiei Kuji
Published 2020-03-01

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure

by Kyoichi Kaira, Kunihiko Kobayashi, Ayako Shiono, Ou Yamaguchi, Kosuke Hashimoto, Atsuto Mouri, Shun Shinomiya, Yu Miura, Hisao Imai, Hiroshi Kagamu
Published 2021-03-01

Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer

by Hisao Imai, Erika Naito, Ou Yamaguchi, Kosuke Hashimoto, Hidetoshi Iemura, Yu Miura, Ayako Shiono, Atsuto Mouri, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu
Published 2022-05-01

Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab

by Ou Yamaguchi, Kyoichi Kaira, Shun Shinomiya, Atsuto Mouri, Kosuke Hashimoto, Ayako Shiono, Yu Miura, Tomoe Akagami, Hisao Imai, Kunihiko Kobayashi, Hiroshi Kagamu
Published 2021-02-01

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib

by Kyoichi Kaira, Hisao Imai, Atsuto Mouri, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Kunihiko Kobayashi, Tomonori Kawasaki, Masanori Yasuda, Hiroshi Kagamu
Published 2023-10-01

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients

by Ayako Shiono, Kyoichi Kaira, Atsuto Mouri, Ou Yamaguchi, Kosuke Hashimoto, Takahiro Uchida, Yu Miura, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu
Published 2019-04-01

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies i...

by Takahiro Uchida, Kyoichi Kaira, Ou Yamaguchi, Atsuto Mouri, Ayako Shiono, Yu Miura, Kosuke Hashimoto, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu
Published 2019-04-01

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers

by Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Shun Shinomiya, Tomoe Akagami, Hisao Imai, Kunihiko Kobayashi, Hiroshi Kagamu
Published 2021-03-01

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer...

by Hisao Imai, Ou Yamaguchi, Keita Mori, Kosuke Hashimoto, Tomoe Akagami, Shun Shinomiya, Yu Miura, Ayako Shiono, Atsuto Mouri, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu
Published 2021-04-01

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab

by Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, Atsuto Mouri, Yu Miura, Ayako Shiono, Fuyumi Nishihara, Yoshitake Murayama, Shin‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu
Published 2019-04-01

Analysis of splice variants of the human protein disulfide isomerase (P4HB) gene

by Daniela Kajihara, Chung-Chau Hon, Aimi Naim Abdullah, João Wosniak, Ana Iochabel S. Moretti, Joice F. Poloni, Diego Bonatto, Kosuke Hashimoto, Piero Carninci, Francisco R. M. Laurindo
Published 2020-11-01

Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation

by Ou Yamaguchi, Kyoichi Kaira, Tomonori Kawasaki, Atsuto Mouri, Kosuke Hashimoto, Ayako Shiono, Shun Shinomiya, Yu Miura, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Satoshi Mochida, Hiroshi Kagamu
Published 2020-04-01

Use of Cap Analysis Gene Expression to detect human papillomavirus promoter activity patterns at different disease stages

by Ayumi Taguchi, Kazunori Nagasaka, Charles Plessy, Hiroe Nakamura, Yoshiko Kawata, Sachi Kato, Kosuke Hashimoto, Takeshi Nagamatsu, Katsutoshi Oda, Iwao Kukimoto, Kei Kawana, Piero Carninci, Yutaka Osuga, Tomoyuki Fujii
Published 2020-10-01

Tumor immunity is related to 18F‐FDG uptake in thymic epithelial tumor

by Hisao Imai, Kyoichi Kaira, Kosuke Hashimoto, Hiroyuki Nitanda, Ryo Taguchi, Akitoshi Yanagihara, Tetsuya Umesaki, Ou Yamaguchi, Atsuto Mouri, Tomonori Kawasaki, Masanori Yasuda, Kunihiko Kobayashi, Hirozo Sakaguchi, Ichiei Kuji, Hiroshi Kagamu
Published 2021-09-01

Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa‐associated lymphoid tissue lymphoma: A case report

by Ayako Shiono, Hisao Imai, Tsugumi Satou, Ryo Taguchi, Naoki Takahashi, Ryuichi Azuma, Ou Yamaguchi, Kosuke Hashimoto, Erika Naito, Hidetoshi Iemura, Yu Miura, Atsuto Mouri, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu
Published 2022-10-01

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events

by Yu Miura, Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Kosuke Hashimoto, Fuyumi Nishihara, Shun Shinomiya, Tomoe Akagami, Yoshitake Murayama, Takanori Abe, Shin‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu
Published 2020-05-01